BioAtla Director Susan Moran Receives 23,500 Share RSU Grant on 18 June 2025

Rhea-AI Filing Summary

Form 4 Filing Overview – BioAtla, Inc. (BCAB)

On 18 June 2025, BioAtla filed a Form 4 disclosing that director Susan Moran acquired 23,500 shares of the company’s common stock through a new time-based restricted stock unit (RSU) grant. The award was recorded with transaction code “A” (acquisition) at a deemed price of $0, reflecting an equity compensation grant rather than an open-market purchase.

The RSU vests 100 % on the earlier of 18 June 2026 or the next annual shareholder meeting, contingent on Ms. Moran’s continued board service. Following the grant, her total beneficial ownership rises to 52,307 shares, all held directly.

No derivative securities, sales, or additional transactions were reported. The filing represents routine director compensation and does not involve cash proceeds, option exercises, or insider sales. While it modestly increases insider ownership, it does not provide new information on BioAtla’s operating performance, strategy, or financial outlook.

Insights

Equity Compensation Analyst

TL;DR: Routine RSU grant increases director’s stake but has negligible immediate valuation impact.

This Form 4 details a standard annual equity award—23,500 RSUs—to director Susan Moran. The one-year cliff vest aligns board incentives with shareholders without near-term cash cost to BioAtla. The incremental ownership (~28 k additional shares versus prior 28.8 k) slightly enhances insider alignment yet is immaterial versus BCAB’s 46 million basic shares outstanding. Because no shares were sold and vesting is service-based, the transaction signals continued board engagement rather than active bullishness. I view the filing as neutral regarding valuation or trading dynamics.

Governance Specialist

TL;DR: Filing confirms standard governance practice; no red flags detected.

The RSU grant follows common small-cap biotech governance norms—annual equity compensation to retain qualified directors while conserving cash. One-year cliff aligns with best-practice guidelines (no accelerated vesting on departure). Power of attorney signature indicates administrative efficiency. Absence of 10b5-1 check box suggests transaction not pre-arranged under a trading plan, which is typical for non-market grants. Overall governance implications are benign; no signs of insider selling or unusual structuring.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Moran Susan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	23,500	$0.00	--

Holdings After Transaction: Common Stock — 52,307 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moran Susan

(Last) (First) (Middle)

C/O BIOATLA, INC. 11085 TORREYANA ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioAtla, Inc. [ BCAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A		23,500(1)	A	$0	52,307	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date.

	/s/ Christian Vasquez, as Attorney-in-Fact for Susan Moran	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BioAtla (BCAB) shares did director Susan Moran acquire?

She received 23,500 restricted stock units representing the same number of common shares.

What is the vesting schedule for the RSUs granted to Susan Moran?

The RSUs vest 100 % on 18 June 2026 or the next annual shareholder meeting, whichever occurs first.

Did the Form 4 report any insider sales of BCAB stock?

No. The filing only reports an acquisition; there were no sales or dispositions mentioned.

What is Susan Moran’s total beneficial ownership after the transaction?

Following the grant, her beneficial ownership is 52,307 BCAB shares, all held directly.

Does the RSU grant impact BioAtla’s cash position?

No. RSUs are a non-cash equity compensation tool, so there is no immediate cash outflow for the company.